Viewray (NASDAQ:VRAY) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday, December 1st.
A number of other analysts also recently commented on the company. Northland Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Viewray in a report on Friday, November 17th. Mizuho reiterated a “buy” rating and issued a $12.00 price target on shares of Viewray in a report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $10.60.
Shares of Viewray (NASDAQ:VRAY) traded down $0.05 during trading hours on Friday, hitting $8.77. The stock had a trading volume of 388,500 shares, compared to its average volume of 729,353. The company has a debt-to-equity ratio of -1.67, a quick ratio of 1.20 and a current ratio of 1.59. Viewray has a fifty-two week low of $3.01 and a fifty-two week high of $10.39.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The business had revenue of $12.20 million during the quarter, compared to the consensus estimate of $18.63 million. Viewray’s quarterly revenue was up 2950.0% compared to the same quarter last year. analysts expect that Viewray will post -0.93 EPS for the current fiscal year.
Several hedge funds have recently modified their holdings of VRAY. Nationwide Fund Advisors lifted its position in shares of Viewray by 843.2% during the second quarter. Nationwide Fund Advisors now owns 16,543 shares of the company’s stock worth $107,000 after purchasing an additional 14,789 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Viewray by 5.0% during the second quarter. HighTower Advisors LLC now owns 21,000 shares of the company’s stock worth $135,000 after purchasing an additional 1,000 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Viewray during the second quarter worth about $159,000. Thompson Siegel & Walmsley LLC bought a new position in shares of Viewray during the third quarter worth about $164,000. Finally, White Pine Capital LLC bought a new position in Viewray in the second quarter worth about $173,000. 50.08% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/12/11/viewray-vray-downgraded-to-sell-at-valuengine.html.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Viewray Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray Inc and related companies with MarketBeat.com's FREE daily email newsletter.